Search Results - c24%3a2

1 Results Sort By:
3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases
Summary: Lung metastases represent a major clinical challenge in advanced cancer, with poor survival rates and no effective therapies to prevent their development. Researchers at the National Cancer Institute (NCI) have developed C24:2, a first-in-class synthetic 3-O-sulfo-galactosylceramide analog. After lysosomal processing by dendritic cells, C24:2...
Published: 9/15/2025   |   Inventor(s): Lise Pasquet, Jay Berzofsky, Amy Howell, Masaki Terabe, Kaddy Camara
Keywords(s): 3-o-sulfo-galactosylceramide Analogs, Berzofsky, C24:2, Immunotherapy, lung cancer, Metastasis, Natural Killer cells, NKT cells, Sulfatide Analogs, T Cells
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology